Embodiments of the subject matter described herein relate generally to fluid infusion devices for delivering a medication fluid to the body of a user. More particularly, embodiments of the subject matter relate to systems for delivering fluid from a fluid reservoir with a wicking membrane.
Certain diseases or conditions may be treated, according to modern medical techniques, by delivering a medication or other substance to the body of a user, either in a continuous manner or at particular times or time intervals within an overall time period. For example, diabetes is commonly treated by delivering defined amounts of insulin to the user at appropriate times. Some common modes of providing insulin therapy to a user include delivery of insulin through manually operated syringes and insulin pens. Other modern systems employ programmable fluid infusion devices (e.g., insulin pumps) to deliver controlled amounts of insulin to a user.
A fluid infusion device suitable for use as an insulin pump may be realized as an external device or an implantable device, which is surgically implanted into the body of the user. External fluid infusion devices include devices designed for use in a generally stationary location (for example, in a hospital or clinic), and devices configured for ambulatory or portable use (to be carried by a user). External fluid infusion devices may establish a fluid flow path from a fluid reservoir to the patient via, for example, a suitable hollow tubing. In certain instances, during fluid delivery, air may become trapped within the fluid reservoir, which may affect fluid delivery accuracy.
Accordingly, it is desirable to provide systems for fluid delivery from a fluid reservoir with a wicking membrane, which ensures fluid delivery accuracy in instances where air may be trapped within the fluid reservoir. Furthermore, other desirable features and characteristics will become apparent from the subsequent detailed description and the appended claims, taken in conjunction with the accompanying drawings and the foregoing technical field and background.
According to the various teachings of the present disclosure, provided is a fluid reservoir system. The fluid reservoir system includes a fluid reservoir that defines a chamber to receive a fluid, and the fluid reservoir includes an outlet. The fluid reservoir system includes a source of pressure to draw the fluid into the outlet and a wicking membrane is coupled to the fluid reservoir that covers the outlet.
Further provided according to various embodiments is a fluid reservoir system. The fluid reservoir system includes a fluid reservoir that defines a chamber to receive a fluid, and the fluid reservoir includes an outlet that defines a fluid flow path. The fluid reservoir system also includes a source of pressure to dispense the fluid through the outlet. The fluid reservoir system includes a hydrophilic wicking membrane coupled to the fluid reservoir so as to be disposed within the chamber. The wicking membrane completely covers the outlet to substantially prevent a flow of air into the fluid flow path.
Also provided is a fluid infusion device. The fluid infusion device includes a fluid reservoir that defines a chamber to receive a fluid. The fluid reservoir includes a first end and a second end, with an outlet formed at the first end to define a fluid flow path. The fluid infusion device includes a drive system having a portion movable within the chamber to dispense the fluid through the outlet. The fluid infusion device also includes a hydrophilic wicking membrane coupled at the first end of the fluid reservoir so as to be disposed entirely within the chamber. The wicking membrane completely covers the outlet to substantially prevent a flow of air into the fluid flow path.
This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
A more complete understanding of the subject matter may be derived by referring to the detailed description and claims when considered in conjunction with the following figures, wherein like reference numbers refer to similar elements throughout the figures.
The following detailed description is merely illustrative in nature and is not intended to limit the embodiments of the subject matter or the application and uses of such embodiments. As used herein, the word “exemplary” means “serving as an example, instance, or illustration.” Any implementation described herein as exemplary is not necessarily to be construed as preferred or advantageous over other implementations. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description.
Certain terminology may be used in the following description for the purpose of reference only, and thus are not intended to be limiting. For example, terms such as “top”, “bottom”, “upper”, “lower”, “above”, and “below” could be used to refer to directions in the drawings to which reference is made. Terms such as “front”, “back”, “rear”, “side”, “outboard”, and “inboard” could be used to describe the orientation and/or location of portions of the component within a consistent but arbitrary frame of reference which is made clear by reference to the text and the associated drawings describing the component under discussion. Such terminology may include the words specifically mentioned above, derivatives thereof, and words of similar import. Similarly, the terms “first”, “second”, and other such numerical terms referring to structures do not imply a sequence or order unless clearly indicated by the context.
The following description relates to a fluid infusion device of the type used to treat a medical condition of a user. The infusion device can be used for infusing fluid into the body of a user. The non-limiting examples described below relate to a medical device used to treat diabetes (more specifically, an insulin pump), although embodiments of the disclosed subject matter are not so limited. Accordingly, the infused medication fluid is insulin in certain embodiments. In alternative embodiments, however, many other fluids may be administered through infusion such as, but not limited to, disease treatments, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-cancer treatments, medications, vitamins, hormones, or the like. For the sake of brevity, conventional features and characteristics related to infusion system operation, insulin pump and/or infusion set operation, fluid reservoirs, and fluid syringes may not be described in detail here. Examples of infusion pumps and/or related pump drive systems used to administer insulin and other medications may be of the type described in, but not limited to: U.S. Patent Publication Nos. 2009/0299290 and 2008/0269687; U.S. Pat. Nos. 4,562,751; 4,678,408; 4,685,903; 5,080,653; 5,505,709; 5,097,122; 6,485,465; 6,554,798; 6,558,351; 6,659,980; 6,752,787; 6,817,990; 6,932,584; 7,621,893; 7,828,764; and 7,905,868; which are each incorporated by reference herein.
With reference to
With reference to
The power supply 110 is any suitable device for supplying the fluid infusion device 100 with power, including, but not limited to, a battery. In one example, the power supply 110 is removable relative to the housing 106; however, the power supply 110 may be fixed within the housing 106. The controller 112 is in communication with the user interface 102 (
The drive system 114 cooperates with the fluid reservoir system 118 to dispense the fluid from the fluid reservoir system 118. In one example, the drive system 114 includes a motor 122, a gear box 124, a drive screw 126 and a slide 128. The motor 122 receives power from the power supply 110. In one example, the motor 122 is an electric motor. The motor 122 includes an output shaft 130, which is coupled to the gear box 124. In one embodiment, the gear box 124 is a reduction gear box. The gear box 124 includes an output shaft 132, which is coupled to the drive screw 126.
The drive screw 126 includes a generally cylindrical distal portion 134 and a generally cylindrical proximal portion 136. The distal portion 134 includes a plurality of threads 138. The threads 138 are generally formed about an exterior circumference of the distal portion 134. The proximal portion 136 is generally unthreaded, and is sized to be received within a portion of the slide 128. Thus, the proximal portion 136 serves to align the drive screw 126 within the slide 128 during assembly, for example.
With continued reference to
The plurality of threads 144 of the slide 128 are formed along an interior surface 128a of the slide 128 between the distal slide end 140 and the proximal slide end 142. Generally, the threads 144 do not extend into the projection 146 of the proximal slide end 142. The threads 144 are formed so as to threadably engage the threads 138 of the drive screw 126. Thus, the rotation of the drive screw 126 causes the linear translation of the slide 128.
In this regard, the slide 128 is generally sized such that in a first, retracted position, the motor 122, the gear box 124 and the drive screw 126 are substantially surrounded by the slide 128. The slide 128 is movable to a second, fully extended position through the operation of the motor 122. The slide 128 is also movable to a plurality of positions between the first, retracted position and the second, fully extended position via the operation of the motor 122. Generally, the operation of the motor 122 rotates the output shaft 130, which is coupled to the gear box 124. The gear box 124 reduces the torque output by the motor 122, and the output shaft 132 of the gear box 124 rotates the drive screw 126, which moves along the threads 144 formed within the slide 128. The movement or rotation of the drive screw 126 relative to the slide 128 causes the movement or linear translation of the slide 128 within the housing 106. The advancement of the slide 128 into a portion of the fluid reservoir system 118 causes the fluid reservoir system 118 to dispense fluid.
With reference to
The fluid reservoir system 118 includes a reservoir cap or connector body 154 and a fluid reservoir 156. The connector body 154 creates a fluid path from the fluid reservoir 156 to the body of the patient. In one exemplary embodiment, the connector body 154 is removably coupled to the housing 106, through any suitable technique, such as threads, press-fitting, etc. Generally, the connector body 154 is suitably sized and configured to accommodate the replacement of fluid reservoirs 156 (which are typically disposable) as needed. A sealing member, such as an O-ring 157 may be coupled between the connector body 154 and the reservoir chamber 106b to prevent the ingress of fluids into the reservoir chamber 106b of the housing 106.
In one example, the connector body 154 accommodates the fluid path from the fluid reservoir 156 to a tubing 158. The tubing 158 represents the fluid flow path that couples the fluid reservoir 156 to an infusion unit to deliver the fluid to the patient (not shown). In one example, the tubing 158 is coupled to the fluid reservoir 156 via a connector needle 160, which is coupled to the connector body 154 and pierces a septum 162 associated with the fluid reservoir 156. It should be noted, however, that any suitable technique could be employed to create a fluid path from the fluid reservoir 156 to the patient, and thus, this embodiment is merely an example.
In one example, the fluid reservoir 156 includes a body or barrel 170, a stopper 172 and a wicking membrane 174. The barrel 170 has a first or distal barrel end 176 and a second or proximal barrel end 178. The barrel 170 defines a fluid chamber for retaining the fluid F. The fluid F is retained within the barrel 170 between the distal barrel end 176 and the proximal barrel end 178. The distal barrel end 176 is positioned adjacent to the slide 128 when the fluid reservoir 156 is assembled in the housing 106. Generally, the distal barrel end 176 has an open perimeter or is circumferentially open such that the slide 128 is receivable within the barrel 170 through the distal barrel end 176. The proximal barrel end 178 defines a port 178a, which receives the connector needle 160 to establish the fluid flow path. The proximal barrel end 178 has any desired shape that mates with at least a portion of the connector body 154.
The stopper 172 is disposed within the barrel 170. The stopper 172 is movable within and relative to the barrel 170 to dispense fluid from the fluid reservoir 156. Stated another way, the stopper 172 is movable within the barrel 170 to pressurize the fluid such that the fluid flows from the barrel 170 through the port 178a into the connector needle 160 and the tubing 158. Thus, the stopper 172 and the drive system 114 cooperate to form a source of pressure for the fluid reservoir system 118. When the barrel 170 is full of fluid, the stopper 172 is adjacent to the distal barrel end 176, and the stopper 172 is movable to a position adjacent to the proximal barrel end 178 to empty the fluid from the fluid reservoir 156. In one example, the stopper 172 is substantially cylindrical, and includes a distal stopper end 180, a proximal stopper end 182, at least one friction element 184 and a counterbore 186 defined from the distal stopper end 180 to the proximal stopper end 182.
The distal stopper end 180 is open about a perimeter of the distal stopper end 180, and thus, is generally circumferentially open. The proximal stopper end 182 is closed about a perimeter of the proximal stopper end 182 and is generally circumferentially closed. The proximal stopper end 182 includes a slightly conical external surface; however, the proximal stopper end 182 can be flat, convex, etc. The at least one friction element 184 is coupled to the stopper 172 about an exterior surface 172a of the stopper 172. In one example, the at least one friction element 184 comprises two friction elements, which include, but are not limited to, O-rings. The friction elements 184 are coupled to circumferential grooves 188 defined in the exterior surface 172a of the stopper 172.
The counterbore 186 receives the projection 146 of the slide 128 and the movement of the slide 128 causes the shoulder 147 of the slide 128 to contact and move the stopper 172. In one example, the counterbore 186 includes threads 190; however, the projection 146 of the slide 128 is not threadably engaged with the stopper 172. Thus, the threads 190 illustrated herein are merely exemplary.
The wicking membrane 174 is coupled within the barrel 170 of the fluid reservoir 156. The wicking membrane 174 is generally coupled to the barrel 170 so as to completely cover an outlet 200 in the barrel 170 defined by the port 178a. The wicking membrane 174 completely covers the outlet 200 to substantially prevent the flow of air into the fluid flow path defined by the outlet 200, the port 178a and the tubing 158. In this example, the wicking membrane 174 is coupled to the barrel 170 at the proximal barrel end 178 such that the entirety of the wicking membrane 174 is disposed in the fluid chamber defined within the barrel 170. It will be understood, however, that the wicking membrane 174 may be coupled to the fluid reservoir 156 such that only the outlet 200 is covered by the wicking membrane 174. Moreover, it should be understood that the wicking membrane 174 may be coupled to the barrel 170 so as to extend from the proximal barrel end 178 to a point located between the proximal barrel end 178 and the distal barrel end 176, if desired. Thus, the wicking membrane 174 as illustrated herein is merely an example.
The wicking membrane 174 includes a first surface 202 substantially opposite a second surface 204. The first surface 202 is disposed within the barrel 170 so as to be in contact with and wetted by the fluid F. The second surface 204 is coupled to an interior surface 170a of the barrel 170 via any suitable technique, such as ultrasonic welding, adhesives, thermal bonding, mechanical fastening (e.g. staples, stitches), etc. Generally, the wicking membrane 174 is coupled to the barrel 170 so as to be fixedly or non-removably coupled to the barrel 170. The wicking membrane 174 may have a substantially small thickness, such as about 0.0762 millimeters (mm) or about 0.003 inches (in.). In this example, the wicking membrane 174 is coupled at the proximal barrel end 178 to enable the stopper 172 to be advanced to the proximal barrel end 178 without contact between the one or more friction elements 184 and the wicking membrane 174. It will be understood, however, that the stopper 172 may be configured to be advanced over a portion of the wicking membrane 174, if desired.
In one example, the wicking membrane 174 is a hydrophilic wicking membrane that draws the fluid F towards the outlet 200 via capillary action. The wicking membrane 174 enables the fluid F to flow from the barrel 170 through the port 178a, while inhibiting or preventing air from exiting through the port 178a. Thus, the wicking membrane 174 may comprise any suitable membrane that enables the passage of a liquid, such as the fluid F, through the membrane via capillary action, while substantially inhibiting the passage of air through the membrane. The first surface 202 of the wicking membrane 174, when wetted by the fluid F, draws the fluid F up through the wicking membrane 174 across a small volume of air due to the surface tension of the fluid F. The first surface 202 may be wetted by the fluid F within the fluid reservoir 156 during the normal use and operation of the fluid reservoir 156.
A pressure difference between the barrel 170 and the tubing 158 also assists the wicking membrane 174 in drawing the liquid or fluid F within the barrel 170 to the port 178a. In this regard, as a pressure within the barrel 170 is higher than a pressure in the tubing 158, the fluid F in the barrel 170 in contact with the first surface 202 of the wicking membrane 174 will be drawn up through the wicking membrane 174 via capillary action through the outlet 200 and out the port 178a.
The wicking membrane 174 may have any suitable pore size to assist in drawing the fluid F through the first surface 202 of the wicking membrane 174 while inhibiting the passage of air through the wicking membrane 174. In one example, the pore size ranges from about 0.1 micrometers (μm) to about 35.0 micrometers (μm). It should be noted that the wicking membrane 174 may have any desired pore size, and moreover, that the pore size may vary over portions of the wicking membrane 174 if desired. Generally, as the average pore size for the wicking membrane 174 decreases, the pressure differential between the barrel 170 and the port 178a required to disrupt the wetted first surface 202 increases (which decreases the likelihood of the introduction of air into the port 178a) and for a given pressure differential the flow rate of the fluid F through the wicking membrane 174 decreases. Thus, the pore size of the wicking membrane 174 may be dependent on the pressure differential between the fluid reservoir 156 and the tubing 158, the surface tension of the fluid F and a desired flow rate for the fluid F. The pore size selected for the wicking membrane 174 may also be dependent on the viscosity of the fluid F, the density of the fluid F, the surface angle between the wicking membrane 174 and the fluid F and the height of the port 178a above a surface of the fluid F. An exemplary hydrophilic wicking membrane 174 for use with the fluid reservoir 156 may comprise about a 0.330 millimeter (mm) or about 0.013 inches (in.) thick fiber membrane with an average pore size of about 5.0 micrometers (μm).
It should be noted that while the wicking membrane 174 is described and illustrated herein as comprising a membrane, the wicking membrane 174 need not be a membrane. In this regard, a series of micro-channels having hydrophilic inner surfaces may be defined or formed in the barrel 170 near the outlet 200. Thus, the wicking membrane 174 is merely an example.
With continued reference to
The pressure increase in the barrel 170 causes a pressure differential between the fluid reservoir 156 and the tubing 158, which is generally at an ambient pressure. The pressure differential assists in dispensing fluid F from the barrel 170 by drawing the fluid F into the tubing 158. Thus, the pressure increase in the barrel 170 acts as a source of positive pressure on the fluid reservoir 156 to draw the fluid into the outlet 200 and cooperates with the wicking membrane 174 to dispense the fluid F from the fluid reservoir 156 with substantially no air entering the outlet 200. With reference to
With reference now to
In this example, the fluid reservoir system 300 comprises a semi-flexible fluid reservoir 302, which may employ a wicking membrane 301 (
In one example, with reference to
In this example, the fluid reservoir 302 includes a first, rigid reservoir wall 308 and a second, flexible reservoir wall 310. The rigid reservoir wall 308 may be composed of any suitable material, for example, a biocompatible polymeric material. The second, flexible reservoir wall 310 may be composed of a suitable flexible material, or a material that has greater flexibility than that of the rigid reservoir wall 308, including, but not limited to a flexible biocompatible material, such as a biocompatible polymer. The flexible reservoir wall 310 is coupled to the rigid reservoir wall 308 between a first or proximal end 312 and a second or distal end 314 of the rigid reservoir wall 308. Generally, the flexible reservoir wall 310 is coupled to the rigid reservoir wall 308 so as to define a fluid chamber 316. It should be noted that while the fluid reservoir 302 is illustrated herein as comprising the rigid reservoir wall 308 and the flexible reservoir wall 310, the fluid reservoir 302 may comprise any number of walls to define a fluid chamber. The fluid chamber 316 receives and contains the fluid F for dispensing.
The rigid reservoir wall 308 also includes an outlet 318. The outlet 318 is defined through the rigid reservoir wall 308 so as to enable fluid communication between the tubing 304 and the fluid chamber 316. The wicking membrane 301 is coupled to the rigid reservoir wall 308 so as to completely cover the outlet 318. The wicking membrane 301 completely covers the outlet 318 to substantially prevent the flow of air 206 into the fluid flow path defined by the outlet 318 and the tubing 304. In this example, the wicking membrane 301 extends from the proximal end 312 of the rigid reservoir wall 308 to a point 319 located near the distal end 314. The wicking membrane 301 is coupled to the rigid reservoir wall 308 such that the entirety of the wicking membrane 301 is disposed in the fluid chamber 316. By covering substantially an entirety of the rigid reservoir wall 308, the wicking membrane 301 assists in wicking the fluid F when the fluid chamber 316 has a low fluid level.
The wicking membrane 301 is coupled to the rigid reservoir wall 308 within the fluid chamber 316. The wicking membrane 301 includes a first surface 320 substantially opposite a second surface 322. The first surface 320 is disposed within the fluid chamber 316 so as to be in contact with and wetted by the fluid F. The second surface 322 is coupled to the rigid reservoir wall 308 via any suitable technique, such as ultrasonic welding, adhesives, thermal bonding, mechanical fastening (e.g. staples, stitches), etc. Generally, the wicking membrane 301 is coupled to the rigid reservoir wall 308 so as to be fixedly or non-removably coupled to the rigid reservoir wall 308. The wicking membrane 301 may also include one or more contours 301a, 301b formed at a first end of the wicking membrane 301 or formed to be adjacent to the outlet 318 when the wicking membrane 301 is coupled to the outlet 318. The contours 301a, 301b may assist in directing a flow of the fluid F from the fluid chamber 316 to the outlet 318.
In one example, the wicking membrane 301 is a hydrophilic wicking membrane that draws fluid via capillary action. The wicking membrane 301 enables the fluid F to flow from the fluid chamber 316 through the outlet 318, while inhibiting or preventing air from exiting through the outlet 318. Thus, the wicking membrane 301 may comprise any suitable membrane that enables the passage of a liquid, such as the fluid F, through the membrane via capillary action, while substantially inhibiting the passage of air through the membrane. The first surface 320 of the wicking membrane 301, when wetted by the fluid F, draws the fluid F up through the wicking membrane 301 across a small volume of air due to the surface tension of the fluid F. The first surface 320 may be wetted by the fluid F within the fluid chamber 316 during the normal use and operation of the fluid chamber 316.
Generally, the pressure difference between the fluid chamber 316 and the tubing 304 created by the source of negative pressure 306 assists the wicking membrane 301 in drawing the liquid or fluid F within the fluid chamber 316 to the outlet 318. In this regard, as a pressure within the fluid chamber 316 is greater than a pressure in the tubing 304, the fluid F in the fluid chamber 316 in contact with the first surface 320 of the wicking membrane 301 will be drawn up through the wicking membrane 301 and out the outlet 318 into the tubing 304. Thus, the source of negative pressure 306 acts on the fluid reservoir 302 to draw the fluid F into the outlet 318 and cooperates with the wicking membrane 301 to dispense the fluid F from the fluid reservoir 302 with substantially no air entering the outlet 318.
The wicking membrane 301 may have any suitable pore size to assist in drawing the fluid F through the first surface 320 of the wicking membrane 301 while inhibiting the passage of air through the wicking membrane 301. In one example, the pore size ranges from about 0.1 micrometers (μm) to about 35.0 micrometers (μm). It should be noted that the wicking membrane 301 may have any desired pore size, and moreover, that the pore size may vary over portions of the wicking membrane 301 if desired. Thus, the pore size of the wicking membrane 301 may be dependent on the pressure differential between the fluid chamber 316 and the tubing 304, the surface tension of the fluid F and a desired flow rate for the fluid F. The pore size selected for the wicking membrane 301 may also be dependent on the viscosity of the fluid F, the density of the fluid F, the surface angle between the wicking membrane 301 and the fluid F and the height of the outlet 318 above a surface of the fluid F. An exemplary hydrophilic wicking membrane 301 for use with the fluid chamber 316 may comprise about a 0.330 millimeter (mm) or about 0.013 inches (in.) thick fiber membrane with an average pore size of about 5.0 micrometers (μm).
It should be noted that while the wicking membrane 301 is described and illustrated herein as comprising a membrane, the wicking membrane 301 need not be a membrane. In this regard, a series of micro-channels having hydrophilic inner surfaces may be defined or formed on the rigid reservoir wall 308 near the outlet 318. Thus, the wicking membrane 301 is merely an example.
With the fluid reservoir system 300 assembled, and the fluid F disposed within the fluid chamber 316, the source of negative pressure 306 applies a negative pressure to the tubing 304. The negative pressure creates a pressure differential between the fluid chamber 316 and the tubing 304. The pressure differential assists in drawing the fluid F up through the wicking membrane 301, through the outlet 318 and into the tubing 304 and prevents substantially all of the air 206 from entering the outlet 318.
With reference now to
In one example, the fluid reservoir system 400 comprises a fully flexible fluid reservoir 402, which may employ the wicking membrane 301. The fluid reservoir 402 is operable to dispense fluid F or create a fluid flow path from the fluid reservoir 402 through the tubing 304. The fluid dispensed by the fluid reservoir system 400 may comprise any suitable fluid, including, but not limited to, disease treatments, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-cancer treatments, medications, vitamins, hormones, insulin or the like. The fluid reservoir system 400 may comprise a stand-alone system for the dispensing of fluid to a patient, or may comprise a portion of a fluid infusion device.
In one example, with reference to
In this example, the fluid reservoir 402 includes a first, flexible reservoir wall 408 and the second, flexible reservoir wall 310. The first, flexible reservoir wall 408 and the second, flexible reservoir wall 310 may be composed of any suitable flexible material, for example, a flexible biocompatible polymeric material. The second, flexible reservoir wall 310 is coupled to the first, flexible reservoir wall 408 between a first or proximal end 412 and a second or distal end 414 of the first, flexible reservoir wall 408. Generally, the second, flexible reservoir wall 310 is coupled to the first, flexible reservoir wall 408 so as to define the fluid chamber 316. It should be noted that while the fluid reservoir 402 is illustrated herein as comprising the first, flexible reservoir wall 408 and the second, flexible reservoir wall 310, the fluid reservoir 402 may comprise any number of walls to define a fluid chamber. The fluid chamber 316 receives and contains the fluid F for dispensing.
The first, flexible reservoir wall 408 also includes an outlet 418. The outlet 418 is defined through the first, flexible reservoir wall 408 so as to enable fluid communication between the tubing 304 and the fluid chamber 316. The wicking membrane 301 is coupled to the first, flexible reservoir wall 408 so as to completely cover the outlet 418. The wicking membrane 301 completely covers the outlet 418 to substantially prevent the flow of air 206 into the fluid flow path defined by the outlet 418 and the tubing 304. The wicking membrane 301 is coupled to the first, flexible reservoir wall 408 such that the entirety of the wicking membrane 301 is disposed in the fluid chamber 316. In this example, the wicking membrane 301 extends from the proximal end 412 of the first, flexible reservoir wall 408 to a point 419 located near the distal end 414. By covering substantially an entirety of the first, flexible reservoir wall 408, the wicking membrane 301 assists in wicking the fluid F when the fluid chamber 316 has a low fluid level.
The wicking membrane 301 is coupled to the first, flexible reservoir wall 408 within the fluid chamber 316. The first surface 320 is disposed within the fluid chamber 316 so as to be in contact with and wetted by the fluid F. The second surface 322 is coupled to the first, flexible reservoir wall 408 via any suitable technique, such as ultrasonic welding, adhesives, thermal bonding, mechanical fastening (e.g. staples, stitches), etc. Generally, the wicking membrane 301 is coupled to the first, flexible reservoir wall 408 so as to be fixedly or non-removably coupled to the first, flexible reservoir wall 408. The wicking membrane 301 may also include the one or more contours 301a, 301b.
The wicking membrane 301 enables the fluid F to flow from the fluid chamber 316 through the outlet 418, while inhibiting or preventing air from exiting through the outlet 418. With the fluid reservoir system 400 assembled, and the fluid F disposed within the fluid chamber 316, the source of negative pressure 306 applies a negative pressure to the tubing 304. The negative pressure creates a pressure differential between the fluid chamber 316 and the tubing 304. The pressure differential assists in drawing the fluid F up through the wicking membrane 301, through the outlet 418 and into the tubing 304. Thus, the source of negative pressure 306 acts on the fluid reservoir 402 to draw the fluid F into the outlet 418 and cooperates with the wicking membrane 301 to dispense the fluid F from the fluid reservoir 402 with substantially no air entering the outlet 418. The wicking membrane 301 prevents substantially all of the air 206 from entering the outlet 418, and thereby improves fluid volume delivery accuracy.
While at least one exemplary embodiment has been presented in the foregoing detailed description, it should be appreciated that a vast number of variations exist. It should also be appreciated that the exemplary embodiment or embodiments described herein are not intended to limit the scope, applicability, or configuration of the claimed subject matter in any way. Rather, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing the described embodiment or embodiments. It should be understood that various changes can be made in the function and arrangement of elements without departing from the scope defined by the claims, which includes known equivalents and foreseeable equivalents at the time of filing this patent application.
Number | Name | Date | Kind |
---|---|---|---|
3631847 | Hobbs, II | Jan 1972 | A |
4212738 | Henne | Jul 1980 | A |
4270532 | Franetzki et al. | Jun 1981 | A |
4282872 | Franetzki et al. | Aug 1981 | A |
4373527 | Fischell | Feb 1983 | A |
4395259 | Prestele et al. | Jul 1983 | A |
4433072 | Pusineri et al. | Feb 1984 | A |
4443218 | Decant, Jr. et al. | Apr 1984 | A |
4494950 | Fischell | Jan 1985 | A |
4542532 | McQuilkin | Sep 1985 | A |
4550731 | Batina et al. | Nov 1985 | A |
4559037 | Franetzki et al. | Dec 1985 | A |
4562751 | Nason et al. | Jan 1986 | A |
4671288 | Gough | Jun 1987 | A |
4678408 | Nason et al. | Jul 1987 | A |
4685903 | Cable et al. | Aug 1987 | A |
4731051 | Fischell | Mar 1988 | A |
4731726 | Allen, III | Mar 1988 | A |
4781798 | Gough | Nov 1988 | A |
4803625 | Fu et al. | Feb 1989 | A |
4809697 | Causey, III et al. | Mar 1989 | A |
4826810 | Aoki | May 1989 | A |
4871351 | Feingold | Oct 1989 | A |
4898578 | Rubalcaba, Jr. | Feb 1990 | A |
5003298 | Havel | Mar 1991 | A |
5011468 | Lundquist et al. | Apr 1991 | A |
5019974 | Beckers | May 1991 | A |
5050612 | Matsumura | Sep 1991 | A |
5078683 | Sancoff et al. | Jan 1992 | A |
5080653 | Voss et al. | Jan 1992 | A |
5097122 | Colman et al. | Mar 1992 | A |
5100380 | Epstein et al. | Mar 1992 | A |
5101814 | Palti | Apr 1992 | A |
5108819 | Heller et al. | Apr 1992 | A |
5114421 | Polak | May 1992 | A |
5153827 | Coutre et al. | Oct 1992 | A |
5165407 | Wilson et al. | Nov 1992 | A |
5247434 | Peterson et al. | Sep 1993 | A |
5262035 | Gregg et al. | Nov 1993 | A |
5262305 | Heller et al. | Nov 1993 | A |
5264104 | Gregg et al. | Nov 1993 | A |
5264105 | Gregg et al. | Nov 1993 | A |
5279608 | Cherif Cheikh | Jan 1994 | A |
5284140 | Allen et al. | Feb 1994 | A |
5299571 | Mastrototaro | Apr 1994 | A |
5307263 | Brown | Apr 1994 | A |
5317506 | Coutre et al. | May 1994 | A |
5320725 | Gregg et al. | Jun 1994 | A |
5322063 | Allen et al. | Jun 1994 | A |
5338157 | Blomquist | Aug 1994 | A |
5339821 | Fujimoto | Aug 1994 | A |
5341291 | Roizen et al. | Aug 1994 | A |
5350411 | Ryan et al. | Sep 1994 | A |
5356786 | Heller et al. | Oct 1994 | A |
5357427 | Langen et al. | Oct 1994 | A |
5368562 | Blomquist et al. | Nov 1994 | A |
5370622 | Livingston et al. | Dec 1994 | A |
5371687 | Holmes, II et al. | Dec 1994 | A |
5376070 | Purvis et al. | Dec 1994 | A |
5390671 | Lord et al. | Feb 1995 | A |
5391250 | Cheney, II et al. | Feb 1995 | A |
5403700 | Heller et al. | Apr 1995 | A |
5411647 | Johnson et al. | May 1995 | A |
5482473 | Lord et al. | Jan 1996 | A |
5485408 | Blomquist | Jan 1996 | A |
5505709 | Funderburk et al. | Apr 1996 | A |
5497772 | Schulman et al. | May 1996 | A |
5543326 | Heller et al. | Aug 1996 | A |
5569186 | Lord et al. | Oct 1996 | A |
5569187 | Kaiser | Oct 1996 | A |
5573506 | Vasko | Nov 1996 | A |
5582593 | Hultman | Dec 1996 | A |
5586553 | Halili et al. | Dec 1996 | A |
5593390 | Castellano et al. | Jan 1997 | A |
5593852 | Heller et al. | Jan 1997 | A |
5594638 | Illiff | Jan 1997 | A |
5609060 | Dent | Mar 1997 | A |
5626144 | Tacklind et al. | May 1997 | A |
5630710 | Tune et al. | May 1997 | A |
5643212 | Coutre et al. | Jul 1997 | A |
5660163 | Schulman et al. | Aug 1997 | A |
5660176 | Iliff | Aug 1997 | A |
5665065 | Colman et al. | Sep 1997 | A |
5665222 | Heller et al. | Sep 1997 | A |
5685844 | Marttila | Nov 1997 | A |
5687734 | Dempsey et al. | Nov 1997 | A |
5704366 | Tacklind et al. | Jan 1998 | A |
5750926 | Schulman et al. | May 1998 | A |
5754111 | Garcia | May 1998 | A |
5764159 | Neftel | Jun 1998 | A |
5772635 | Dastur et al. | Jun 1998 | A |
5779665 | Mastrototaro et al. | Jul 1998 | A |
5788669 | Peterson | Aug 1998 | A |
5791344 | Schulman et al. | Aug 1998 | A |
5800420 | Gross et al. | Sep 1998 | A |
5807336 | Russo et al. | Sep 1998 | A |
5814015 | Gargano et al. | Sep 1998 | A |
5822715 | Worthington et al. | Oct 1998 | A |
5832448 | Brown | Nov 1998 | A |
5840020 | Heinonen et al. | Nov 1998 | A |
5861018 | Feierbach et al. | Jan 1999 | A |
5868669 | Iliff | Feb 1999 | A |
5871465 | Vasko | Feb 1999 | A |
5879163 | Brown et al. | Mar 1999 | A |
5885245 | Lynch et al. | Mar 1999 | A |
5897493 | Brown | Apr 1999 | A |
5899855 | Brown | May 1999 | A |
5904708 | Goedeke | May 1999 | A |
5913310 | Brown | Jun 1999 | A |
5917346 | Gord | Jun 1999 | A |
5918603 | Brown | Jul 1999 | A |
5925021 | Castellano et al. | Jul 1999 | A |
5933136 | Brown | Aug 1999 | A |
5935099 | Peterson et al. | Aug 1999 | A |
5940801 | Brown | Aug 1999 | A |
5956501 | Brown | Sep 1999 | A |
5960403 | Brown | Sep 1999 | A |
5965380 | Heller et al. | Oct 1999 | A |
5972199 | Heller et al. | Oct 1999 | A |
5978236 | Faberman et al. | Nov 1999 | A |
5997476 | Brown | Dec 1999 | A |
5999848 | Gord et al. | Dec 1999 | A |
5999849 | Gord et al. | Dec 1999 | A |
6009339 | Bentsen et al. | Dec 1999 | A |
6032119 | Brown et al. | Feb 2000 | A |
6043437 | Schulman et al. | Mar 2000 | A |
6081736 | Colvin et al. | Jun 2000 | A |
6083710 | Heller et al. | Jul 2000 | A |
6088608 | Schulman et al. | Jul 2000 | A |
6101478 | Brown | Aug 2000 | A |
6103033 | Say et al. | Aug 2000 | A |
6119028 | Schulman et al. | Sep 2000 | A |
6120676 | Heller et al. | Sep 2000 | A |
6121009 | Heller et al. | Sep 2000 | A |
6134461 | Say et al. | Oct 2000 | A |
6143164 | Heller et al. | Nov 2000 | A |
6162611 | Heller et al. | Dec 2000 | A |
6175752 | Say et al. | Jan 2001 | B1 |
6183412 | Benkowski et al. | Feb 2001 | B1 |
6246992 | Brown | Jun 2001 | B1 |
6259937 | Schulman et al. | Jul 2001 | B1 |
6329161 | Heller et al. | Dec 2001 | B1 |
6408330 | DeLaHuerga | Jun 2002 | B1 |
6424847 | Mastrototaro et al. | Jul 2002 | B1 |
6472122 | Schulman et al. | Oct 2002 | B1 |
6484045 | Holker et al. | Nov 2002 | B1 |
6484046 | Say et al. | Nov 2002 | B1 |
6485465 | Moberg et al. | Nov 2002 | B2 |
6503381 | Gotoh et al. | Jan 2003 | B1 |
6514718 | Heller et al. | Feb 2003 | B2 |
6544173 | West et al. | Apr 2003 | B2 |
6553263 | Meadows et al. | Apr 2003 | B1 |
6554798 | Mann et al. | Apr 2003 | B1 |
6558320 | Causey, III et al. | May 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6560741 | Gerety et al. | May 2003 | B1 |
6565509 | Say et al. | May 2003 | B1 |
6579690 | Bonnecaze et al. | Jun 2003 | B1 |
6591125 | Buse et al. | Jul 2003 | B1 |
6592745 | Feldman et al. | Jul 2003 | B1 |
6605200 | Mao et al. | Aug 2003 | B1 |
6605201 | Mao et al. | Aug 2003 | B1 |
6607658 | Heller et al. | Aug 2003 | B1 |
6616819 | Liamos et al. | Sep 2003 | B1 |
6618934 | Feldman et al. | Sep 2003 | B1 |
6623501 | Heller et al. | Sep 2003 | B2 |
6641533 | Causey, III et al. | Nov 2003 | B2 |
6654625 | Say et al. | Nov 2003 | B1 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6671554 | Gibson et al. | Dec 2003 | B2 |
6676816 | Mao et al. | Jan 2004 | B2 |
6689265 | Heller et al. | Feb 2004 | B2 |
6728576 | Thompson et al. | Apr 2004 | B2 |
6733471 | Ericson et al. | May 2004 | B1 |
6746582 | Heller et al. | Jun 2004 | B2 |
6747556 | Medema et al. | Jun 2004 | B2 |
6749740 | Liamos et al. | Jun 2004 | B2 |
6752787 | Causey, III et al. | Jun 2004 | B1 |
6809653 | Mann et al. | Oct 2004 | B1 |
6817990 | Yap et al. | Nov 2004 | B2 |
6881551 | Heller et al. | Apr 2005 | B2 |
6892085 | McIvor et al. | May 2005 | B2 |
6893545 | Gotoh et al. | May 2005 | B2 |
6895263 | Shin et al. | May 2005 | B2 |
6916169 | Rush et al. | Jul 2005 | B2 |
6932584 | Gray et al. | Aug 2005 | B2 |
6932894 | Mao et al. | Aug 2005 | B2 |
6942518 | Liamos et al. | Sep 2005 | B2 |
7153263 | Carter et al. | Dec 2006 | B2 |
7153289 | Vasko | Dec 2006 | B2 |
7396330 | Banet et al. | Jul 2008 | B2 |
7621893 | Moberg et al. | Nov 2009 | B2 |
7828764 | Moberg et al. | Nov 2010 | B2 |
7905868 | Moberg et al. | Mar 2011 | B2 |
20010044731 | Coffman et al. | Nov 2001 | A1 |
20020013518 | West et al. | Jan 2002 | A1 |
20020055857 | Mault et al. | May 2002 | A1 |
20020082665 | Haller et al. | Jun 2002 | A1 |
20020093192 | Matkovich | Jul 2002 | A1 |
20020137997 | Mastrototaro et al. | Sep 2002 | A1 |
20020161288 | Shin et al. | Oct 2002 | A1 |
20030060765 | Campbell et al. | Mar 2003 | A1 |
20030078560 | Miller et al. | Apr 2003 | A1 |
20030088166 | Say et al. | May 2003 | A1 |
20030144581 | Conn et al. | Jul 2003 | A1 |
20030152823 | Heller | Aug 2003 | A1 |
20030176183 | Drucker et al. | Sep 2003 | A1 |
20030188427 | Say et al. | Oct 2003 | A1 |
20030199744 | Buse et al. | Oct 2003 | A1 |
20030208113 | Mault et al. | Nov 2003 | A1 |
20030220552 | Reghabi et al. | Nov 2003 | A1 |
20040061232 | Shah et al. | Apr 2004 | A1 |
20040061234 | Shah et al. | Apr 2004 | A1 |
20040064133 | Miller et al. | Apr 2004 | A1 |
20040064156 | Shah et al. | Apr 2004 | A1 |
20040073095 | Causey, III et al. | Apr 2004 | A1 |
20040074785 | Holker et al. | Apr 2004 | A1 |
20040093167 | Braig et al. | May 2004 | A1 |
20040097796 | Berman et al. | May 2004 | A1 |
20040102683 | Khanuja et al. | May 2004 | A1 |
20040111017 | Say et al. | Jun 2004 | A1 |
20040122353 | Shahmirian et al. | Jun 2004 | A1 |
20040167465 | Mihai et al. | Aug 2004 | A1 |
20040263354 | Mann et al. | Dec 2004 | A1 |
20050038331 | Silaski et al. | Feb 2005 | A1 |
20050038680 | McMahon et al. | Feb 2005 | A1 |
20050154271 | Rasdal et al. | Jul 2005 | A1 |
20050192557 | Brauker et al. | Sep 2005 | A1 |
20060229694 | Schulman et al. | Oct 2006 | A1 |
20060238333 | Welch et al. | Oct 2006 | A1 |
20060293571 | Bao et al. | Dec 2006 | A1 |
20070088521 | Shmueli et al. | Apr 2007 | A1 |
20070135866 | Baker et al. | Jun 2007 | A1 |
20080154503 | Wittenber et al. | Jun 2008 | A1 |
20080269682 | Kavazov | Oct 2008 | A1 |
20080269687 | Chong et al. | Oct 2008 | A1 |
20080294100 | de Costa | Nov 2008 | A1 |
20090081951 | Erdmann et al. | Mar 2009 | A1 |
20090082635 | Baldus et al. | Mar 2009 | A1 |
20090299290 | Moberg | Dec 2009 | A1 |
20110060274 | Kuhn | Mar 2011 | A1 |
20120035543 | Kamen | Feb 2012 | A1 |
20130253439 | Wyss | Sep 2013 | A1 |
20130296825 | Lerner | Nov 2013 | A1 |
20140039456 | Lerner | Feb 2014 | A1 |
20140358111 | Brewer | Dec 2014 | A1 |
20150018765 | Wong et al. | Jan 2015 | A1 |
Number | Date | Country |
---|---|---|
4329229 | Mar 1995 | DE |
0319268 | Nov 1988 | EP |
0806738 | Nov 1997 | EP |
0880936 | Dec 1998 | EP |
1338295 | Aug 2003 | EP |
1631036 | Mar 2006 | EP |
2455126 | May 2012 | EP |
2623142 | Aug 2013 | EP |
2218831 | Nov 1989 | GB |
WO 9620745 | Jul 1996 | WO |
WO 9636389 | Nov 1996 | WO |
WO 9637246 | Nov 1996 | WO |
WO 9721456 | Jun 1997 | WO |
WO 9820439 | May 1998 | WO |
WO 9824358 | Jun 1998 | WO |
WO 9842407 | Oct 1998 | WO |
WO 9849659 | Nov 1998 | WO |
WO 9859487 | Dec 1998 | WO |
WO 9908183 | Feb 1999 | WO |
WO 9910801 | Mar 1999 | WO |
WO 9918532 | Apr 1999 | WO |
WO 9922236 | May 1999 | WO |
WO 0010628 | Mar 2000 | WO |
WO 0019887 | Apr 2000 | WO |
WO 0048112 | Aug 2000 | WO |
WO 02058537 | Aug 2002 | WO |
WO 03001329 | Jan 2003 | WO |
WO 03094090 | Nov 2003 | WO |
WO 2005065538 | Jul 2005 | WO |
Entry |
---|
PCT Search Report (PCT/US02/03299), dated Oct. 31, 2002, Medtronic Minimed, Inc. |
(Animas Corporation, 1999). Animas . . . bringing new life to insulin therapy. |
Bode B W, et al. (1996). Reduction in Severe Hypoglycemia with Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes. Diabetes Care, vol. 19, No. 4, 324-327. |
Boland E (1998). Teens Pumping it Up! Insulin Pump Therapy Guide for Adolescents. 2nd Edition. |
Brackenridge B P (1992). Carbohydrate Gram Counting a Key to Accurate Mealtime Boluses in Intensive Diabetes Therapy. Practical Diabetology, vol. 11, No. 2, pp. 22-28. |
Brackenridge, B P et al. (1995). Counting Carbohydrates How to Zero in on Good Control. MiniMed Technologies Inc. |
Farkas-Hirsch R et al. (1994). Continuous Subcutaneous Insulin Infusion: A Review of the Past and Its Implementation for the Future. Diabetes Spectrum From Research to Practice, vol. 7, No. 2, pp. 80-84, 136-138. |
Hirsch I B et al. (1990). Intensive Insulin Therapy for Treatment of Type I Diabetes. Diabetes Care, vol. 13, No. 12, pp. 1265-1283. |
Kulkarni K et al. (1999). Carbohydrate Counting A Primer for Insulin Pump Users to Zero in on Good Control. MiniMed Inc. |
Marcus A O et al. (1996). Insulin Pump Therapy Acceptable Alternative to Injection Therapy. Postgraduate Medicine, vol. 99, No. 3, pp. 125-142. |
Reed J et al. (1996). Voice of the Diabetic, vol. 11, No. 3, pp. 1-38. |
Skyler J S (1989). Continuous Subcutaneous Insulin Infusion [CSII] With External Devices: Current Status. Update in Drug Delivery Systems, Chapter 13, pp. 163-183. Futura Publishing Company. |
Skyler J S et al. (1995). The Insulin Pump Therapy Book Insights from the Experts. MiniMed⋅Technologies. |
Strowig S M (1993). Initiation and Management of Insulin Pump Therapy. The Diabetes Educator, vol. 19, No. 1, pp. 50-60. |
Walsh J, et al. (1989). Pumping Insulin: The Art of Using an Insulin Pump. Published by MiniMed⋅Technologies. |
(Intensive Diabetes Management, 1995). Insulin Infusion Pump Therapy. pp. 66-78. |
(MiniMed, 1996). The MiniMed 506. 7 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054527/www.minimed.com/files/506_pic.htm. |
(MiniMed, 1997). MiniMed 507 Specifications. 2 pages. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234841/www.minimed.com/files/mmn075.htm. |
(MiniMed, 1996). FAQ: The Practical Things . . . pp. 1-4. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19961111054546/www.minimed.com/files/faq_pract.htm. |
(MiniMed, 1997). Wanted: a Few Good Belt Clips! 1 page. Retrieved on Sep. 16, 2003 from the World Wide Web: http://web.archive.org/web/19970124234559/www.minimed.com/files/mmn002.htm. |
(MiniMed Technologies, 1994). MiniMed 506 Insulin Pump User's Guide. |
(MiniMed Technologies, 1994). MiniMed™ Dosage Calculator Initial Meal Bolus Guidelines / MiniMed™ Dosage Calculator Initial Basal Rate Guidelines Percentage Method. 4 pages. |
(MiniMed, 1996). MiniMed™ 507 Insulin Pump User's Guide. |
(MiniMed, 1997). MiniMed™ 507 Insulin Pump User's Guide. |
(MiniMed, 1998). MiniMed 507C Insulin Pump User's Guide. |
(MiniMed International, 1998). MiniMed 507C Insulin Pump For those who appreciate the difference. |
(MiniMed inc., 1999). MiniMed 508 Flipchart Guide to Insulin Pump Therapy. |
(MiniMed Inc., 1999). Insulin Pump Comparison / Pump Therapy Will Change Your Life. |
(MiniMed, 2000). MiniMed® 508 User's Guide. |
(MiniMed Inc., 2000). MiniMed® Now [I] Can Meal Bolus Calculator / MiniMed® Now [I] Can Correction Bolus Calculator. |
(MiniMed Inc., 2000). Now [I] Can MiniMed Pump Therapy. |
(MiniMed Inc., 2000). Now [I] Can MiniMed Diabetes Management. |
(Medtronic MiniMed, 2002). The 508 Insulin Pump A Tradition of Excellence. |
(Medtronic MiniMed, 2002). Medtronic MiniMed Meal Bolus Calculator and Correction Bolus Calculator. International Version. |
Abel, P., et al., “Experience with an implantable glucose sensor as a prerequiste of an artificial beta cell,” Biomed. Biochim. Acta 43 (1984) 5, pp. 577-584. |
Bindra, Dilbir S., et al., “Design and in Vitro Studies of a Needle-Type Glucose Sensor for a Subcutaneous Monitoring,” American Chemistry Society, 1991, 63, pp. 1692-1696. |
Boguslavsky, Leonid, et al., “Applications of redox polymers in biosensors,” Sold State Ionics 60, 1993, pp. 189-197. |
Geise, Robert J., et al., “Electropolymerized 1,3-diaminobenzene for the construction of a 1,1′-dimethylferrocene mediated glucose biosensor,” Analytica Chimica Acta, 281, 1993, pp. 467-473. |
Gernet, S., et al., “A Planar Glucose Enzyme Electrode,” Sensors and Actuators, 17, 1989, pp. 537-540. |
Gernet, S., et al., “Fabrication and Characterization of a Planar Electromechanical Cell and its Application as a Glucose Sensor,” Sensors and Actuators, 18, 1989, pp. 59-70. |
Gorton, L., et al., “Amperometric Biosensors Based on an Apparent Direct Electron Transfer Between Electrodes and Immobilized Peroxiases,” Analyst, Aug. 1991, vol. 117, pp. 1235-1241. |
Gorton, L., et al., “Amperometric Glucose Sensors Based on Immobilized Glucose-Oxidizing Enymes and Chemically Modified Electrodes,” Analytica Chimica Acta, 249, 1991, pp. 43-54. |
Gough, D. A., et al., “Two-Dimensional Enzyme Electrode Sensor for Glucose,” Analytical Chemistry, vol. 57, No. 5, 1985, pp. 2351-2357. |
Gregg, Brian A., et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Biosensor Applications,” Analytical Chemistry, 62, pp. 258-263. |
Gregg, Brian A., et al., “Redox Polymer Films Containing Enzymes. 1. A Redox-Conducting Epoxy Cement: Synthesis, Characterization, and Electrocatalytic Oxidation of Hydroquinone,” The Journal of Physical Chemistry, vol. 95, No. 15, 1991, pp. 5970-5975. |
Hashiguchi, Yasuhiro, MD, et al., “Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor With Microdialysis Sampling Method,” Diabetes Care, vol. 17, No. 5, May 1994, pp. 387-389. |
Heller, Adam, “Electrical Wiring of Redox Enzymes,” Acc. Chem. Res., vol. 23, No. 5, May 1990, pp. 128-134. |
Jobst, Gerhard, et al., “Thin-Film Microbiosensors for Glucose-Lactate Monitoring,” Analytical Chemistry, vol. 68, No. 18, Sep. 15, 1996, pp. 3173-3179. |
Johnson, K.W., et al., “In vivo evaluation of an electroenzymatic glucose sensor implanted in subcutaneous tissue,” Biosensors & Bioelectronics, 7, 1992, pp. 709-714. |
Jönsson, G., et al., “An Electromechanical Sensor for Hydrogen Peroxide Based on Peroxidase Adsorbed on a Spectrographic Graphite Electrode,” Electroanalysis, 1989, pp. 465-468. |
Kanapieniene, J. J., et al., “Miniature Glucose Biosensor with Extended Linearity,” Sensors and Actuators, B. 10, 1992, pp. 37-40. |
Kawamori, Ryuzo, et al., “Perfect Normalization of Excessive Glucagon Responses to Intraveneous Arginine in Human Diabetes Mellitus With the Artificial Beta-Cell,” Diabetes vol. 29, Sep. 1980, pp. 762-765. |
Kimura, J., et al., “An Immobilized Enzyme Membrane Fabrication Method,” Biosensors 4, 1988, pp. 41-52. |
Koudelka, M., et al., “In-vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors,” Biosensors & Bioelectronics 6, 1991, pp. 31-36. |
Koudelka, M., et al., “Planar Amperometric Enzyme-Based Glucose Microelectrode,” Sensors & Actuators, 18, 1989, pp. 157-165. |
Mastrototaro, John J., et al., “An electroenzymatic glucose sensor fabricated on a flexible substrate,” Sensors & Actuators, B. 5, 1991, pp. 139-144. |
Mastrototaro, John J., et al., “An Electroenzymatic Sensor Capable of 72 Hour Continuous Monitoring of Subcutaneous Glucose,” 14th Annual International Diabetes Federation Congress, Washington D.C., Jun. 23-28, 1991. |
McKean, Brian D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors,” IEEE Transactions on Biomedical Engineering, Vo. 35, No. 7, Jul. 1988, pp. 526-532. |
Monroe, D., “Novel Implantable Glucose Sensors,” ACL, Dec. 1989, pp. 8-16. |
Morff, Robert J., et al., “Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors,” Annuaal International Conference of teh IEEE Engineering in Medicine and Biology Society, Vo. 12, No. 2, 1990, pp. 483-484. |
Moussy, Francis, et al., “Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating,” Analytical Chemistry, vol. 65, No. 15, Aug. 1, 1993, pp. 2072-2077. |
Nakamoto, S., et al., “A Lift-Off Method for Patterning Enzyme-Immobilized Membranes in Multi-Biosensors,” Sensors and Actuators 13, 1988, pp. 165-172. |
Nishida, Kenro, et al., “Clinical applications of teh wearable artifical endocrine pancreas with the newly designed needle-type glucose sensor,” Elsevier Sciences B.V., 1994, pp. 353-358. |
Nishida, Kenro, et al., “Development of a ferrocene-mediated needle-type glucose sensor covereed with newly designd biocompatible membrane, 2-methacryloyloxyethylphosphorylcholine-co-n-butyl nethacrylate,” Medical Progress Through Technology, vol. 21, 1995, pp. 91-103. |
Poitout, V., et al., “A glucose monitoring system for on line estimation oin man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue adn a wearable control unit,” Diabetologia, vol. 36, 1991, pp. 658-663. |
Reach, G., “A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors,” Biosensors 2, 1986, pp. 211-220. |
Shaw, G. W., et al., “In vitro testing of a simply constructed, highly stable glucose sensor suitable for implantation in diabetic patients,” Biosensors & Bioelectronics 6, 1991, pp. 401-406. |
Shichiri, M., “A Needle-Type Glucose Sensor—A Valuable Tool Not Only for a Self-Blood Glucose Monitoring but for a Wearable Artifiical Pancreas,” Life Support Systems Proceedings, XI Annual Meeting ESAO, Alpbach-Innsbruck, Austria, Sep. 1984, pp. 7-9. |
Shichiri, Motoaki, et al., “An artificial endocrine pancreas—problems awaiting solution for long-term clinical applications of a glucose sensor,” Frontiers Med. Biol. Engng., 1991, vol. 3, No. 4, pp. 283-292. |
Shichiri, Motoaki, et al., “Closed-Loop Glycemic Control with a Wearable Artificial Endocrine Pancreas—Variations in Daily Insulin Requirements to Glycemic Response,” Diabetes, vol. 33, Dec. 1984, pp. 1200-1202. |
Shichiri, Motoaki, et al., “Glycaemic Control in a Pacreatectomized Dogs with a Wearable Artificial Endocrine Pancreas,” Diabetologia, vol. 24, 1983, pp. 179-184. |
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers,” Hormone and Metabolic Research, Supplement Series vol. No. 20, 1988, pp. 17-20. |
Shichiri, M., et al., “Membrane design for extending the long-life of an implantable glucose sensor,” Diab. Nutr. Metab., vol. 2, No. 4, 1989, pp. 309-313. |
Shichiri, Motoaki, et al., “Normalization of the Paradoxic Secretion of Glucagon in Diabetes Who Were Controlled by the Artificial Beta Cell,” Diabetes, vol. 28, Apr. 1979, pp. 272-275. |
Shichiri, Motoaki, et al., “Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A useful Tool for Blood Glucose Monitoring in Diabetic Individuals,” Diabetes Care, vol. 9, No. 3, May-Jun. 1986, pp. 298-301. |
Shichiri, Motoaki, et al., “Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor,” The Lancet, Nov. 20, 1982, pp. 1129-1131. |
Shichiri, Motoaki, et al., “The Wearable Artificial Endocrine Pancreas with a Needle-Type Glucose Sensor: Perfect Glycemic Control in Ambulatory Diabetes,” Acta Paediatr Jpn 1984, vol. 26, pp. 359-370. |
Shinkai, Seiji, “Molecular Recognitiion of Mono- and Di-saccharides by Phenylboronic Acids in Solvent Extraction and as a Monolayer,” J. Chem. Soc., Chem. Commun., 1991, pp. 1039-1041. |
Shults, Mark C., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors,” IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, Oct. 1994, pp. 937-942. |
Sternberg, Robert, et al., “Study and Development of Multilayer Needle-type Enzyme-based Glucose Microsensors,” Biosensors, vol. 4, 1988, pp. 27-40. |
Tamiya, E., et al., “Micro Glucose Sensors using Electron Mediators Immobilized on a Polypyrrole-Modified Electrode,” Sensors and Actuators, vol. 18, 1989, pp. 297-307. |
Tsukagoshi, Kazuhiko, et al., “Specific Complexation with Mono- and Disaccharides that can be Detected by Circular Dichroism,” J. Org. Chem., vol. 56, 1991, pp. 4089-4091. |
Urban, G., et al., “Miniaturized multi-enzyme biosensors integrated with pH sensors on flexible polymer carriers for in vivo applciations,” Biosensors & Bioelectronics, vol. 7, 1992, pp. 733-739. |
Ubran, G., et al., “Miniaturized thin-film biosensors using covalently immobilized glucose oxidase,” Biosensors & Bioelectronics, vol. 6, 1991, pp. 555-562. |
Velho, G., et al, “In vivo calibration of a subcutaneous glucose sensor for determination of subcutaneous glucose kinetics,” Diab. Nutr. Metab., vol. 3, 1988, pp. 227-233. |
Wang, Joseph, et al., “Needle-Type Dual Microsensor for the Simultaneous Monitoring of Glucose and Insulin,” Analytical Chemistry, vol. 73, 2001, pp. 844-847. |
Yamasaki, Yoshimitsu, et al., “Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor,” Clinics Chimica Acta, vol. 93, 1989, pp. 93-98. |
Yokoyama, K., “Integrated Biosensor for Glucose and Galactose,” Analytica Chimica Acta, vol. 218, 1989, pp. 137-142. |
Number | Date | Country | |
---|---|---|---|
20170143914 A1 | May 2017 | US |